BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 34745768)

  • 41. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma.
    Li JW; Shi D; Wan XC; Hu J; Su YF; Zeng YP; Hu ZJ; Yu BH; Zhang QL; Wei P; Zhou XY
    Oncoimmunology; 2021; 10(1):1995166. PubMed ID: 34745768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
    Signorelli D; Ghidotti P; Proto C; Brambilla M; De Toma A; Ferrara R; Galli G; Ganzinelli M; Lo Russo G; Prelaj A; Occhipinti M; Viscardi G; Capizzuto V; Pontis F; Petraroia I; Ferretti AM; Colombo MP; Torri V; Sozzi G; Garassino MC; Jachetti E; Fortunato O
    Front Immunol; 2022; 13():987639. PubMed ID: 36203609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9.
    Mathieu M; Névo N; Jouve M; Valenzuela JI; Maurin M; Verweij FJ; Palmulli R; Lankar D; Dingli F; Loew D; Rubinstein E; Boncompain G; Perez F; Théry C
    Nat Commun; 2021 Jul; 12(1):4389. PubMed ID: 34282141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exosome-based liquid biopsies in cancer: opportunities and challenges.
    Yu W; Hurley J; Roberts D; Chakrabortty SK; Enderle D; Noerholm M; Breakefield XO; Skog JK
    Ann Oncol; 2021 Apr; 32(4):466-477. PubMed ID: 33548389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
    Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
    Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications.
    He X; Zhong X; Hu Z; Zhao S; Wei P; Li D
    Clin Transl Med; 2020 Dec; 10(8):e249. PubMed ID: 33377655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma extracellular vesicles detected by Single Molecule array technology as a liquid biopsy for colorectal cancer.
    Wei P; Wu F; Kang B; Sun X; Heskia F; Pachot A; Liang J; Li D
    J Extracell Vesicles; 2020 Aug; 9(1):1809765. PubMed ID: 32944195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.
    Cordonnier M; Nardin C; Chanteloup G; Derangere V; Algros MP; Arnould L; Garrido C; Aubin F; Gobbo J
    J Extracell Vesicles; 2020; 9(1):1710899. PubMed ID: 32002173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of exosomal shuttle RNA (esRNA) in lymphoma.
    Li J; Tian T; Zhou X
    Crit Rev Oncol Hematol; 2019 May; 137():27-34. PubMed ID: 31014513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
    Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
    Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Specific Decrease in B-Cell-Derived Extracellular Vesicles Enhances Post-Chemotherapeutic CD8
    Zhang F; Li R; Yang Y; Shi C; Shen Y; Lu C; Chen Y; Zhou W; Lin A; Yu L; Zhang W; Xue Z; Wang J; Cai Z
    Immunity; 2019 Mar; 50(3):738-750.e7. PubMed ID: 30770248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
    J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.